Skip to content
Peptidepedia

Semaglutide Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

Weeks 1–4 (0.25 mg): Initial appetite suppression typically begins within the first week. Small amounts of weight loss may happen during this period. Some users report reduced food cravings and decreased interest in snacking. Gastrointestinal adjustment occurs during this period.

Weeks 5–12 (0.5–1.0 mg): If the dose is increased, then pronounced appetite reduction and consistent weight loss starts to happen during this time. Improved fasting glucose levels become measurable. Energy levels may fluctuate as caloric intake decreases.

Weeks 13–20 (1.7–2.4 mg): Significant improvements in waist circumference, blood pressure, and lipid profiles. Most gastrointestinal side effects resolve or become manageable, especially if the dose has been maintained for at least 8 weeks.

Weeks 20–68: The STEP 1 trial demonstrated average weight loss of 14.9% at 68 weeks with 2.4 mg weekly dosing, with approximately one-third of participants achieving ≥20% weight reduction. Continued use maintains weight loss; discontinuation typically results in gradual regain.

Frequently Asked Questions

Most users notice appetite changes within the first week, with measurable weight loss of 5% typically achieved by weeks 8 to 12, though specific timelines vary across individuals. Maximum effects occur at maintenance dosing, with average losses of 15% at one year.

Clinical data shows most individuals regain a significant portion of lost weight within 1 to 2 years of discontinuation. Sustainable lifestyle changes during treatment improve long-term outcomes.

Current evidence supports safety with continuous use for several years. Ongoing post-marketing surveillance continues to monitor long-term outcomes. The cardiovascular benefits observed in trials suggest favorable risk-benefit profiles for indicated populations.

Eat smaller, more frequent meals; avoid fatty or greasy foods; stay hydrated; eat slowly; and avoid lying down immediately after eating. Nausea typically improves after 4–8 weeks at each dose level.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. FDA Approval Announcement for Wegovy (2021).
  2. Semaglutide Mechanism of Action Review. PMC.
  3. Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
  4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
  5. Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity (STEP 4). JAMA. 2021.
  6. Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021.
  7. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM. 2023.
  8. Wegovy Prescribing Information. FDA.
  9. FDA Statement on Compounded Semaglutide.
←Read the full Semaglutide guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”